| Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update SK Sarin, M Kumar, GK Lau, Z Abbas, HLY Chan, CJ Chen, DS Chen, ... Hepatology international 10, 1-98, 2016 | 2577 | 2016 |
| Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B GKK Lau, T Piratvisuth, KX Luo, P Marcellin, S Thongsawat, G Cooksley, ... New England Journal of Medicine 352 (26), 2682-2695, 2005 | 1987 | 2005 |
| Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B P Marcellin, GKK Lau, F Bonino, P Farci, S Hadziyannis, R Jin, ZM Lu, ... New England Journal of Medicine 351 (12), 1206-1217, 2004 | 1523 | 2004 |
| Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update YF Liaw, N Leung, JH Kao, T Piratvisuth, E Gane, KH Han, R Guan, ... Hepatology international 2, 263-283, 2008 | 1264 | 2008 |
| Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update YF Liaw, JH Kao, T Piratvisuth, HLY Chan, RN Chien, CJ Liu, E Gane, ... Hepatology international 6, 531-561, 2012 | 1255 | 2012 |
| Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B WGE Cooksley, T Piratvisuth, SD Lee, V Mahachai, YC Chao, ... Journal of viral hepatitis 10 (4), 298-305, 2003 | 744 | 2003 |
| A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt W Sievert, I Altraif, HA Razavi, A Abdo, EA Ahmed, A AlOmair, ... Liver international 31, 61-80, 2011 | 691 | 2011 |
| Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B MR Brunetto, F Moriconi, F Bonino, GKK Lau, P Farci, C Yurdaydin, ... Hepatology 49 (4), 1141-1150, 2009 | 667 | 2009 |
| Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B EB Keeffe, S Zeuzem, RS Koff, DT Dieterich, R Esteban–Mur, EJ Gane, ... Clinical Gastroenterology and Hepatology 5 (8), 890-897, 2007 | 504 | 2007 |
| Factors that predict response of patients with hepatitis B e antigen–Positive chronic hepatitis B to peginterferon-alfa EHCJ Buster, BE Hansen, GKK Lau, T Piratvisuth, S Zeuzem, ... Gastroenterology 137 (6), 2002-2009, 2009 | 501 | 2009 |
| Hepatitis B surface antigen quantification: why and how to use it in 2011–a core group report HLY Chan, A Thompson, M Martinot-Peignoux, T Piratvisuth, M Cornberg, ... Journal of hepatology 55 (5), 1121-1131, 2011 | 437 | 2011 |
| Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a P Marcellin, F Bonino, GKK Lau, P Farci, C Yurdaydin, T Piratvisuth, R Jin, ... Gastroenterology 136 (7), 2169-2179. e4, 2009 | 410 | 2009 |
| Liver biopsy: complications and risk factors P Thampanitchawong, T Piratvisuth World journal of gastroenterology 5 (4), 301, 1999 | 368 | 1999 |
| HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B MW Fried, T Piratvisuth, GKK Lau, P Marcellin, WC Chow, G Cooksley, ... Hepatology 47 (2), 428-434, 2008 | 351 | 2008 |
| Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B F Bonino, P Marcellin, GKK Lau, S Hadziyannis, R Jin, T Piratvisuth, ... Gut 56 (5), 699-705, 2007 | 319 | 2007 |
| Drinking to cope during COVID‐19 pandemic: The role of external and internal factors in coping motive pathways to alcohol use, solitary drinking, and alcohol problems JD Wardell, T Kempe, KK Rapinda, A Single, E Bilevicius, JR Frohlich, ... Alcoholism: Clinical and Experimental Research 44 (10), 2073-2083, 2020 | 317 | 2020 |
| Response‐guided peginterferon therapy in hepatitis B e antigen‐positive chronic hepatitis B using serum hepatitis B surface antigen levels MJ Sonneveld, BE Hansen, T Piratvisuth, JD Jia, S Zeuzem, E Gane, ... Hepatology 58 (3), 872-880, 2013 | 291 | 2013 |
| Shorter durations and lower doses of peginterferon alfa‐2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C YF Liaw, JD Jia, HLY Chan, KH Han, T Tanwandee, WL Chuang, DM Tan, ... Hepatology 54 (5), 1591-1599, 2011 | 265 | 2011 |
| Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study) SK Sarin, A Choudhury, GK Lau, MH Zheng, D Ji, S Abd-Elsalam, ... Hepatology international 14, 690-700, 2020 | 238 | 2020 |
| Peginterferon alfa-2a HBeAg-positive chronic hepatitis B study group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B GK Lau, T Piratvisuth, KX Luo, P Marcellin, S Thongsawat, G Cooksley, ... N Engl J Med 352 (26), 2682-2695, 2005 | 229 | 2005 |
